July 23, 2024
Postmenopausal Osteoporosis Market

Postmenopausal Osteoporosis Market Is Estimated To Witness High Growth Owing To Increasing Awareness and Rising Geriatric Population

The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4,547.8 million in 2022 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Postmenopausal osteoporosis is a condition characterized by the loss of bone mass and deterioration of bone tissue, leading to an increased risk of fractures. It primarily affects women after menopause due to hormonal changes. The market offers various treatment options, including bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, and monoclonal antibodies. These treatments aim to prevent bone loss and reduce the risk of fractures in postmenopausal women.

Market Dynamics:

The two major drivers fueling the growth of the Postmenopausal Osteoporosis Market are increasing awareness about osteoporosis and its consequences and the rising geriatric population. With better education and awareness campaigns, more women are seeking medical help for early detection and treatment of osteoporosis. Additionally, the growing aging population contributes to market growth as the risk of developing osteoporosis increases with age.

Segment Analysis:

In the Postmenopausal Osteoporosis Market, bisphosphonates are the dominating segment. Bisphosphonates are widely prescribed due to their effectiveness in reducing bone loss and decreasing fracture risk. They are available in both oral and injectable forms, providing convenience and flexibility for patients.

PEST Analysis:


Governments worldwide are taking initiatives to raise awareness about osteoporosis and promote bone health programs.


The increasing healthcare expenditure and rising disposable income in developing countries are driving market growth.


The aging population and changing lifestyle factors such as sedentary habits and poor nutrition contribute to the prevalence of osteoporosis.


Advancements in diagnostic techniques and the introduction of innovative treatment options are positively impacting the market.

Key Takeaways:

– The global Postmenopausal Osteoporosis Market is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period, due to increasing awareness about osteoporosis and the rising geriatric population.

– North America is the fastest-growing and dominating region in the market, attributed to the high prevalence of osteoporosis and the availability of advanced healthcare infrastructure.

– Key players operating in the global Postmenopausal Osteoporosis Market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCEND HOLDING, Amgen, Gedeon Richter Plc, Enzene Biosciences, Samsung Bioepis, Radius Health, Inc., Alvotech, and AryoGen Pharmed. These companies focus on strategic collaborations, product launches, and mergers to gain a competitive edge in the market.

In conclusion, the Postmenopausal Osteoporosis Market is expected to grow significantly in the coming years, driven by increasing awareness about osteoporosis, the rising geriatric population, and advancements in treatment options. Governments and healthcare organizations are also playing a crucial role in promoting bone health and early detection of osteoporosis, further propelling market growth.